Dianthus Therapeutics to present at J.P. Morgan Healthcare Conference on January 15, 2025, discussing antibody therapies for autoimmune diseases.
Quiver AI Summary
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company focused on next-generation antibody complement therapeutics for severe autoimmune diseases, will participate in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Marino Garcia is set to deliver a corporate overview on January 15, 2025, at 9:00 a.m. PST in San Francisco, and a live webcast of the presentation will be available on the company's website. Based in New York and Waltham, Dianthus Therapeutics is committed to developing innovative monoclonal antibodies with enhanced selectivity and potency to transform treatment options for patients with serious autoimmune and inflammatory conditions.
Potential Positives
- Dianthus Therapeutics will present at the prestigious 43rd Annual J.P. Morgan Healthcare Conference, a major event in the healthcare industry, which can enhance the company's visibility and credibility.
- The presentation by the CEO indicates a proactive approach in communicating the company's progress and strategic vision to investors and stakeholders.
- The focus on advancing next-generation antibody complement therapeutics aligns with current trends in biopharmaceutical innovation, potentially attracting investor interest and funding opportunities.
Potential Negatives
- Company is in a clinical-stage, indicating that it has not yet brought any products to market, which may raise concerns about its ability to generate revenue.
- Company's participation in a major conference may suggest it is seeking additional funding or partnerships, which can indicate potential financial instability.
FAQ
What is the date and time of Dianthus Therapeutics' presentation at the J.P. Morgan Healthcare Conference?
Dianthus Therapeutics will present on January 15, 2025, at 9:00 a.m. PST / 12:00 p.m. EST.
Where can I watch the Dianthus Therapeutics conference presentation?
The presentation will be available via a live webcast in the "News and Events" section of the Dianthus Therapeutics website.
What is the focus of Dianthus Therapeutics?
Dianthus Therapeutics focuses on developing next-generation antibody complement therapeutics for severe autoimmune diseases.
Who is presenting for Dianthus Therapeutics at the conference?
Marino Garcia, the Chief Executive Officer, will present the corporate overview.
How can I learn more about Dianthus Therapeutics?
Visit the Dianthus Therapeutics website at www.dianthustx.com and follow them on LinkedIn for more information.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$DNTH Hedge Fund Activity
We have seen 55 institutional investors add shares of $DNTH stock to their portfolio, and 25 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALLIANCEBERNSTEIN L.P. added 998,133 shares (+3990.9%) to their portfolio in Q3 2024
- GREAT POINT PARTNERS LLC removed 482,929 shares (-63.7%) from their portfolio in Q3 2024
- STATE STREET CORP added 413,425 shares (+101.4%) to their portfolio in Q3 2024
- VR ADVISER, LLC removed 350,000 shares (-16.7%) from their portfolio in Q3 2024
- JANUS HENDERSON GROUP PLC added 273,670 shares (+40.5%) to their portfolio in Q3 2024
- POINT72 ASSET MANAGEMENT, L.P. added 263,500 shares (+151.3%) to their portfolio in Q3 2024
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 250,000 shares (-100.0%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEW YORK and WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation at the 43
rd
Annual J.P. Morgan Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Wednesday, January 15, 2025 at 9:00 a.m. PST / 12:00 p.m. EST in San Francisco.
A live webcast of the Company’s presentation may be accessed under “News and Events” in the
Investors
section of the Dianthus Therapeutics
website
.
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit
www.dianthustx.com
and follow us on
LinkedIn
.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
